SEARCH

SEARCH BY CITATION

References

  • 1
    Vlachopoulos C, Aznaouridis K, Stefanadis C. Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis. J Am Coll Cardiol. 2010;55:13181327.
  • 2
    Tomiyama H, Yamashina A. Non-invasive vascular function tests: their pathophysiological background and clinical application. Circ J. 2010;74:2433.
  • 3
    Tomlinson LA. Methods for assessing arterial stiffness: technical considerations. Curr Opin Nephrol Hypertens. 2012;21:655660.
  • 4
    Laurent S, Boutouyrie P. Arterial stiffness: a new surrogate end point for cardiovascular disease? J Nephrol. 2007;20(Suppl 12):S45S50.
  • 5
    Wang X, Keith JC Jr, Struthers AD, et al. Assessment of arterial stiffness, a translational medicine biomarker system for evaluation of vascular risk. Cardiovasc Ther. 2008;26:214223.
  • 6
    Persy V, D'Haese P. Vascular calcification and bone disease: the calcification paradox. Trends Mol Med. 2009;15:405416.
  • 7
    Venuraju SM, Yerramasu A, Corder R, et al. Osteoprotegerin as a predictor of coronary artery disease and cardiovascular mortality and morbidity. J Am Coll Cardiol. 2010;55:20492061.
  • 8
    Speer G, Fekete BC, El Hadj Othmane T, et al. Serum osteoprotegerin level, carotid-femoral pulse wave velocity and cardiovascular survival in haemodialysis patients. Nephrol Dial Transplant. 2008;23:32563262.
  • 9
    Kiechl S, Schett G, Wenning G, et al. Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation. 2004;109:21752180.
  • 10
    Blacher J, Asmar R, Djane S, et al. Aortic pulse wave velocity as a marker of cardiovascular risk in hypertensive patients. Hypertension. 1999;33:11111117.
  • 11
    Boutouyrie P, Tropeano AI, Asmar R, et al. Aortic stiffness is an independent predictor of primary coronary events in hypertensive patients: a longitudinal study. Hypertension. 2002;39:1015.
  • 12
    Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. I. Diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med. 1998;15:539553.
  • 13
    Hunt SA, Abraham WT, Chin MH, et al. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation. 2009;119:e391e479.
  • 14
    Hsu BG, Chen YC, Lee RP, et al. Fasting serum level of fatty-acid-binding protein 4 positively correlates with metabolic syndrome in patients with coronary artery disease. Circ J. 2010;74:327331.
  • 15
    Hsu BG, Ho GJ, Lee CJ, et al. Inverse association of serum long-acting natriuretic peptide and bone mass density in renal transplant recipients. Clin Transplant. 2012;26:E105E110.
  • 16
    Norton GR, Majane OH, Maseko MJ, et al. Brachial blood pressure-independent relations between radial late systolic shoulder-derived aortic pressures and target organ changes. Hypertension. 2012;59:885892.
  • 17
    Sonne-Holm S, Sørensen TI, Jensen G, et al. Independent effects of weight change and attained body weight on prevalence of arterial hypertension in obese and non-obese men. BMJ. 1989;299:767770.
  • 18
    Landsberg L, Aronne LJ, Beilin LJ, et al. Obesity-related hypertension: pathogenesis, cardiovascular risk, and treatment-A position paper of The Obesity Society and the American Society of Hypertension. J Clin Hypertens (Greenwich). 2013;15:1433.
  • 19
    Chuang SY, Hsu PF, Chang HY, et al. C-reactive protein predicts systolic blood pressure and pulse pressure but not diastolic blood pressure: the cardiovascular disease risk factors two-township study. Am J Hypertens. 2013;26:657664.
  • 20
    Lakatta EG. Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises: Part III: cellular and molecular clues to heart and arterial aging. Circulation. 2003;107:490497.
  • 21
    Stehouwer CD, Henry RM, Ferreira I. Arterial stiffness in diabetes and the metabolic syndrome: a pathway to cardiovascular disease. Diabetologia. 2008;51:527539.
  • 22
    van den Bogaard B, Holleboom AG, Duivenvoorden R, et al. Patients with low HDL-cholesterol caused by mutations in LCAT have increased arterial stiffness. Atherosclerosis. 2012;225:481485.
  • 23
    Wang F, Ye P, Luo L, et al. Association of serum lipids with arterial stiffness in a population-based study in Beijing. Eur J Clin Invest. 2011;41:929936.
  • 24
    Wang X, Du Y, Fan L, et al. Relationships between HDL-C, hs-CRP, with Central Arterial Stiffness in Apparently Healthy People Undergoing a General Health Examination. PLoS ONE. 2013;8:e81778.
  • 25
    Besler C, Lüscher TF, Landmesser U. Molecular mechanisms of vascular effects of high-density lipoprotein: alterations in cardiovascular disease. EMBO Mol Med. 2012;4:251268.
  • 26
    Briet M, Boutouyrie P, Laurent S, et al. Arterial stiffness and pulse pressure in CKD and ESRD. Kidney Int. 2012;82:388400.
  • 27
    Bian SY, Guo HY, Ye P, et al. Association of glomerular filtration rate with arterial stiffness in Chinese women with normal to mildly impaired renal function. J Geriatr Cardiol. 2012;9:158165.
  • 28
    Schillaci G, Pirro M, Mannarino MR, et al. Relation between renal function within the normal range and central and peripheral arterial stiffness in hypertension. Hypertension. 2006;48:616621.
  • 29
    Andrade J, Er L, Ignaszewski A, Levin A. Exploration of association of 1, 25-OH2D3 with augmentation index, a composite measure of arterial stiffness. Clin J Am Soc Nephrol. 2008;3:18001806.
  • 30
    Van Campenhout A, Golledge J. Osteoprotegerin, vascular calcification and atherosclerosis. Atherosclerosis. 2009;204:321329.
  • 31
    Zagura M, Serg M, Kampus P, et al. Association of osteoprotegerin with aortic stiffness in patients with symptomatic peripheral artery disease and in healthy subjects. Am J Hypertens. 2010;23:586591.
  • 32
    Scialla JJ, Leonard MB, Townsend RR, et al. Correlates of osteoprotegerin and association with aortic pulse wave velocity in patients with chronic kidney disease. Clin J Am Soc Nephrol. 2011;6:26122619.
  • 33
    Nakashima A, Carrero JJ, Qureshi AR, et al. Plasma osteoprotegerin, arterial stiffness, and mortality in normoalbuminemic Japanese hemodialysis patients. Osteoporos Int. 2011;22:16951701.
  • 34
    Tousoulis D, Siasos G, Maniatis K, et al. Serum osteoprotegerin and osteopontin levels are associated with arterial stiffness and the presence and severity of coronary artery disease. Int J Cardiol. 2013;167:19241928.
  • 35
    Karalliedde J, Smith A, DeAngelis L, et al. Valsartan improves arterial stiffness in type 2 diabetes independently of blood pressure lowering. Hypertension. 2008;51:16171623.
  • 36
    Williams B. Evaluating interventions to reduce central aortic pressure, arterial stiffness and morbidity–mortality. J Hypertens. 2012;30(Suppl):S13S18.
  • 37
    Rizos EC, Agouridis AP, Elisaf MS. The effect of statin therapy on arterial stiffness by measuring pulse wave velocity: a systematic review. Curr Vasc Pharmacol. 2010;8:638644.